Your browser doesn't support javascript.
loading
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
Murray, Joseph A; Kelly, Ciarán P; Green, Peter H R; Marcantonio, Annette; Wu, Tsung-Teh; Mäki, Markku; Adelman, Daniel C.
Afiliação
  • Murray JA; Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: murray.joseph@mayo.edu.
  • Kelly CP; Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Green PHR; Columbia University College of Physicians and Surgeons, New York, New York.
  • Marcantonio A; Alvine Pharmaceuticals, San Carlos, California.
  • Wu TT; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Mäki M; School of Medicine, University of Tampere and Tampere University Hospital, Tampere, Finland.
  • Adelman DC; Alvine Pharmaceuticals, San Carlos, California.
Gastroenterology ; 152(4): 787-798.e2, 2017 03.
Article em En | MEDLINE | ID: mdl-27864127

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Doença Celíaca / Duodeno / Mucosa Intestinal Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gastroenterology Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Doença Celíaca / Duodeno / Mucosa Intestinal Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gastroenterology Ano de publicação: 2017 Tipo de documento: Article